U.S. Ambassador to Egypt Herro Mustafa Garg recently joined Egyptian officials, including Prime Minister Dr. Mostafa Madbouly, to witness the signing of a key agreement between Dawah Pharmaceuticals, a U.S. company, and Gypto Pharma, an Egyptian firm. The companies plan to establish new pharmaceutical manufacturing facilities in Egypt, featuring advanced American technology.
This collaboration aims to address the pharmaceutical market demand in Egypt while expanding export opportunities to regions such as the United States, Europe, Africa, and the MENA region. As a result, the initiative is expected to benefit both U.S. and Egyptian economies by increasing American exports to Egypt and setting up manufacturing facilities within the country.
Ambassador Mustafa Garg highlighted the importance of this agreement, saying, "The critical element of this landmark agreement between Dawah Pharmaceuticals and Gypto Pharma is the supply of state-of-the art U.S. machinery, equipment, and technologies along with the know-how and expertise to expand the reach of Egyptian pharmaceutical production throughout Africa and the Middle East. This partnership showcases the strength of our bilateral economic relationship and the shared prosperity it brings to both Egypt and the United States."
The partnership is anticipated to create job opportunities and boost trade and investment in both nations. Gypto Pharma has plans to construct a biosimilar manufacturing plant and a bioequivalence testing facility in New Jersey as part of the initial phase of the collaboration.